Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours By Ogkologos - February 10, 2026 257 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRIDENT-1 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Extension of Indications for Tegafur December 24, 2021 SIOG 2020: New Research in Caring for and Treating People With... November 12, 2020 Re-Thinking Community December 10, 2021 Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST... March 10, 2026 Load more HOT NEWS 2023 ASCO Annual Meeting Research Round Up: Advances in Treating Gynecologic... Beloved Jeopardy! Host Alex Trebek Has Passed Away After Battle with... As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... Group of Breast Cancer Survivors is Finding New Strength from Fitness...
